Patents Assigned to Heparegenix GMBH
  • PROTEIN KINASE MKK4 INHIBITORS FOR PROMOTING LIVER REGENERATION OR REDUCING OR PREVENTING HEPATOCYTE DEATH
    Publication number: 20240116931
    Abstract: The invention relates to pyrazolo-pyridine compounds which inhibit mitogen-activated protein kinase kinase 4 (MKK4) and in particular, selectively inhibit MKK4 over protein kinases JNK1 and MKK7. The compounds are useful for promoting liver regeneration or reducing or preventing hepatocyte death. They are further useful for treating osteoarthritis or rheumatoid arthritis, or CNS-related diseases.
    Type: Application
    Filed: November 8, 2023
    Publication date: April 11, 2024
    Applicant: HEPAREGENIX GMBH
    Inventors: Brent PRAEFKE, Philip KLÖVEKORN, Roland SELIG, Wolfgang ALBRECHT, Stefan LAUFER
  • Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
    Patent number: 11912701
    Abstract: The invention relates to compounds of formula (I) which are inhibitors of MKK4 (mitogen-activated protein kinase kinase 4) and their use in promoting liver regeneration or reducing or preventing hepatocyte death. The compounds selectively inhibit protein kinase MKK4 over protein kinases JNK and MKK7. (I), wherein Rx, Ry, Rz and Rzz are selected from: a) Rx and Ry are F and Rz and Rzz are H; b) Rx, Ry and Rzz are independently halogen and Rz is H; c) Rx Rz and Rzz are independently halogen and Ry is H; and d) Rx Ry and Rz are independently halogen and Rzz is H.
    Type: Grant
    Filed: July 16, 2019
    Date of Patent: February 27, 2024
    Assignee: HepaRegeniX GmbH
    Inventors: Wolfgang Albrecht, Stefan Laufer, Roland Selig, Phillip Klövekorn, Bent Präfke
  • Protein kinase MKK4 inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
    Patent number: 11858927
    Abstract: The invention relates to pyrazolo-pyridine compounds which inhibit mitogen-activated protein kinase kinase 4 (MKK4) and in particular, selectively inhibit MKK4 over protein kinases JNK1 and MKK7. The compounds are useful for promoting liver regeneration or reducing or preventing hepatocyte death. They are further useful for treating osteoarthritis or rheumatoid arthritis, or CNS-related diseases.
    Type: Grant
    Filed: January 30, 2019
    Date of Patent: January 2, 2024
    Assignee: HepaRegeniX GmbH
    Inventors: Bent Praefke, Philip Klövekorn, Roland Selig, Wolfgang Albrecht, Stefan Laufer
  • Tricyclic protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
    Patent number: 11731968
    Abstract: Tricyclic mitogen-activated protein kinases kinase 4 (MKK4) inhibitor compounds useful for promoting liver regeneration or reducing hepatocyte death by selectively inhibiting MKK4 over protein kinases JNK and MKK7.
    Type: Grant
    Filed: June 18, 2019
    Date of Patent: August 22, 2023
    Assignee: HepaRegeniX GmbH
    Inventors: Michael Juchum, Roland Selig, Stefan Laufer, Wolfgang Albrecht
  • Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
    Patent number: 11040027
    Abstract: The invention relates to MKK4 (mitogen-activated protein kinase 4) and their use in promoting liver regeneration or reducing or preventing hepatocyte death. The MKK4 inhibitors selectively inhibit protein kinase MKK4 over protein kinases JNK and MKK7.
    Type: Grant
    Filed: January 17, 2018
    Date of Patent: June 22, 2021
    Assignee: Heparegenix GMBH
    Inventors: Wolfgang Albrecht, Stefan Laufer, Roland Selig, Phillip Klövekorn, Bent Präfke